Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Non-Current Liabilities (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $390.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 12.14% year-over-year to $390.2 million, compared with a TTM value of $390.2 million through Dec 2025, up 12.14%, and an annual FY2025 reading of $390.2 million, up 12.14% over the prior year.
  • Total Non-Current Liabilities was $390.2 million for Q4 2025 at Karyopharm Therapeutics, up from $292.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $390.2 million in Q4 2025 and bottomed at $237.9 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $296.4 million, with a median of $275.6 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 55.64% in 2024, then dropped 29.86% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $252.0 million in 2021, then dropped by 3.92% to $242.1 million in 2022, then surged by 55.16% to $375.7 million in 2023, then decreased by 7.36% to $348.0 million in 2024, then increased by 12.14% to $390.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for KPTI at $390.2 million in Q4 2025, $292.0 million in Q3 2025, and $335.5 million in Q2 2025.